Leadership change
Swiss biotech company Anaveon has appointed a new Chief Executive Officer. As the company announced in March, experienced biopharma executive Thaminda Ramanayake will take over the leadership of the Basel-based firm.
ADVERTISEMENT
About Maren Kühr
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 284 entries already.
Entries by Maren Kühr
Is the Unified Patent Court affordable for small biotechs?
The Unified Patent Court and the unitary patent were established to make patent litigation in Europe easier, faster and more affordable. It has been particularly emphasized that the new system was designed to enable small and medium-sized enterprises to enforce their rights more effectively and rapidly. The reality now suggests differently. Litigation in Europe has become quite fragmented, more complex and more expensive than ever – a nice playground for deep pockets.
New CFO with Novartis experience
In March, Mukul Mehta took over as the new Chief Financial Officer at Basel-based Biotech and Pharma Company Novartis. At the same time, he became a member of the Executive Committee.
New CCO strengthens global business strategy
Bristol-based cell and gene therapy CDMO eXmoor Pharma appointed Manuel Balbuena as Chief Commercial Officer at the beginning of March.
Return as new Chief Financial Officer
Jurgen Berendsen has returned to Symeres (Nijmegen, NL) as Chief Financial Officer. His appointment took place at the beginning of this year.
New COO takes over
Cambridge-based techbio company Qureight Ltd has appointed Rebecca Simmons as its new Chief Operating Officer in January.
PL BioScience: Pioneering the Future of Cell Culture
With the promise of transformative treatments, cell therapies are rising across oncology, regenerative medicine, and stem cell applications. PL BioScience supports this evolution with Human Platelet Lysate (HPL) and soon, the first artificial HPL, while expanding production in Aachen to continue to deliver this high-quality cell culture supplement worldwide.
miRNA discovery & development platform
Pharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) and seeks for co-development partners and/or early stage investors. PH also offers its miRNA discovery and development service platform that includes efficacy testing from in vitro to large animal models in various therapeutic areas.
Europe’s moment: We could be the heroes of biotech
Capital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.
Antibodies: Cornerstone of ADC precision and efficacy
Antibody-drug conjugates (ADCs) hinge on the antibody, not merely the payload or linker. Antibody precision defines efficacy, safety and therapeutic window. Emerging antibody formats – bispecifics, conditional designs and TCR-mimics – expand target space, demanding rigorous engineering to realise next-generation ADC potential.